1
|
Woon W, Samuel J, Wahab K, Zaini F, Hamadi F, Ck AL, Ramamurthy V, Bohari S. A phantom study investigating effective strategies for reducing fetal dose in pregnant patients with head and neck cancer. J Med Imaging Radiat Sci 2024; 55:264-271. [PMID: 38553300 DOI: 10.1016/j.jmir.2024.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 02/06/2024] [Accepted: 02/28/2024] [Indexed: 06/12/2024]
Abstract
PURPOSE To measure the out-of-field doses for various treatment planning techniques and assess the impact on fetal dose with and without the use of custom shielding. MATERIALS AND METHODS A total of six treatment plans were generated with different treatment techniques such as 3-dimensional conformal radiation therapy (3DCRT), intensity modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT), utilizing both 6 MV flattened beams and flattening filter-free (FFF) beams. The measurements were carried out both out-of-field at the surface and at depth to assess the dose reduction achieved by removing the flattening filter and incorporating shielding. RESULTS The custom-made frame shielding can effectively reduce the surface dose with a maximum reduction of 15.2% observed in VMAT plans and achieve a maximum reduction of 100% for cone beam computed tomography (CBCT) imaging. Out-of-field dose measurements conducted at depth, positioned 58 cm inferior to the target isocenter, reveal that the shielding effectiveness consistently remains the greatest for 3DCRT technique. A maximum reduction of 21% is observed when utilizing a flattening filter-free beam. CONCLUSION The results of this study indicate that the 3DCRT technique exhibits the least amount of scatter radiation both near and far from the treatment isocenter, which is the most suitable approach for radiation therapy of pregnant patients. In cases where meeting dose constraints for critical organs becomes challenging, VMAT technique emerges as the most suitable treatment technique for reducing out-of-field doses. Additionally, a flattening filter-free beam significantly reduces out-of-field doses due to lower contributions from head scatter.
Collapse
Affiliation(s)
- WuiAnn Woon
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam.
| | - Jacob Samuel
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Khairina Wahab
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Farhan Zaini
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Fatin Hamadi
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Andrew Lee Ck
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Vedapriya Ramamurthy
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| | - Shahidda Bohari
- Department of Radiation Oncology, The Brunei Cancer Center, Bandar Seri Begawan, BG3122, Brunei Darussalam
| |
Collapse
|
2
|
Wong YM, Koh CWY, Lew KS, Chua CGA, Nei W, Tan HQ, Lee JCL, Mazonakis M, Damilakis J. A review on fetal dose in Radiotherapy: A historical to contemporary perspective. Phys Med 2023; 105:102513. [PMID: 36565555 DOI: 10.1016/j.ejmp.2022.102513] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 11/09/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
This paper aims to review on fetal dose in radiotherapy and extends and updates on a previous work1 to include proton therapy. Out-of-field doses, which are the doses received by regions outside of the treatment field, are unavoidable regardless of the treatment modalities used during radiotherapy. In the case of pregnant patients, fetal dose is a major concern as it has long been recognized that fetuses exposed to radiation have a higher probability of suffering from adverse effects such as anatomical malformations and even fetal death, especially when the 0.1Gy threshold is exceeded. In spite of the low occurrence of cancer during pregnancy, the radiotherapy team should be equipped with the necessary knowledge to deal with fetal dose. This is crucial so as to ensure that the fetus is adequately protected while not compromising the patient treatment outcomes. In this review paper, various aspects of fetal dose will be discussed ranging from biological, clinical to the physics aspects. Other than fetal dose resulting from conventional photon therapy, this paper will also extend the discussion to modern treatment modalities and techniques, namely proton therapy and image-guided radiotherapy, all of which have seen a significant increase in use in current radiotherapy. This review is expected to provide readers with a comprehensive understanding of fetal dose in radiotherapy, and to be fully aware of the steps to be taken in providing radiotherapy for pregnant patients.
Collapse
Affiliation(s)
- Yun Ming Wong
- Division of Physics and Applied Physics, Nanyang Technological University, Singapore
| | | | - Kah Seng Lew
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | | | - Wenlong Nei
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | - Hong Qi Tan
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
| | - James Cheow Lei Lee
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Division of Physics and Applied Physics, Nanyang Technological University, Singapore
| | - Michael Mazonakis
- Department of Medical Physics, School of Medicine, University of Crete, Greece
| | - John Damilakis
- Department of Medical Physics, School of Medicine, University of Crete, Greece
| |
Collapse
|
3
|
Karbhari N, Thomas AA. Clinical management of brain tumors in pregnancy. Curr Opin Oncol 2022; 34:691-697. [PMID: 36170169 DOI: 10.1097/cco.0000000000000894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW We review the diagnostic tools, treatment options, and clinical management for brain tumors diagnosed in pregnancy with consideration for management approaches that are best suited to preserve maternal and fetal health. RECENT FINDINGS Women of child-bearing age are at risk of developing brain tumors and are at increased risk compared with male counterparts for tumors that are hormonally driven. Brain tumors are rare neoplasms, and diagnosis of brain tumors in pregnancy is uncommon, such that management guidelines and treatment recommendations are lacking for most tumor types. We discuss the standard treatment options for brain tumors and the relative risks and safety when these treatments are considered during pregnancy. We review the neoplasms most commonly affecting pregnant women and the existing literature and guidelines. SUMMARY Pregnancy is a unique phase of life in which hormonal, immunologic, and vascular changes may impact tumor growth and presentation. Treatment decisions should consider the symptoms and stability of the pregnant patients, the gestational age and health of the fetus, and the location and behavior of the neoplasm.
Collapse
Affiliation(s)
- Nishika Karbhari
- Department of Neurology, Dartmouth Hitchcock Medical Center, Hanover, NH
| | - Alissa A Thomas
- Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, VT, USA
| |
Collapse
|
4
|
Goyal S, Yadav A, Madan R, Chitkara A, Singh R, Khosla D, Kumar N. Managing brain tumors in pregnancy: The oncologist's struggle with maternal-fetal conflict. J Cancer Res Ther 2022; 18:5-18. [DOI: 10.4103/jcrt.jcrt_1343_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
5
|
Oonsiri P, Vannavijit C, Wimolnoch M, Suriyapee S, Saksornchai K. Estimated radiation doses to ovarian and uterine organs in breast cancer irradiation using radio-photoluminescent glass dosimeters (RPLDs). J Med Radiat Sci 2021; 68:167-174. [PMID: 33078910 PMCID: PMC8168059 DOI: 10.1002/jmrs.445] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2020] [Revised: 09/04/2020] [Accepted: 09/30/2020] [Indexed: 11/05/2022] Open
Abstract
INTRODUCTION The well-being of breast cancer patients is essential, especially fertility in patients of reproductive age. The objective of this study was to estimate the radiation doses to the ovaries and uterus for different treatment techniques of breast cancer irradiation using radio-photoluminescent glass dosimeters (RPLDs). METHODS A Farmer-type ionisation chamber (IBA FC-65G) and RPLDs were used to measure in- and out-of-field radiation doses in a solid water phantom. The field sizes were set to 10 × 10 cm2 and 8 × 17 cm2 with the central axis at out-of-field measurement distances of 30 or 50 cm. The Rando phantom's left breast was planned using four different techniques: two tangential standard fields with and without electronic tissue compensator (E-comp) techniques, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). The radiation doses in the ipsilateral ovary, contralateral ovary and uterus were measured using RPLDs. RESULTS The percentage ratio of out of field to in field was affected by distance from the central axis to the point of measurement, in addition to the field sizes associated with collimator scatter. Advanced techniques such as IMRT and VMAT produced higher doses to the ovaries and uterus. The estimated results of the worst-case scenario for the ipsilateral ovary, contralateral ovary and uterus were 0.84% (42 cGy), 0.62% (31 cGy) and 0.76% (38 cGy), respectively, for a 5000 cGy prescription dose. CONCLUSION The lowest to highest out-of-field radiation doses to the ovarian and uterine organs from breast irradiation were the two tangential field techniques, VMAT and IMRT. These advanced techniques yielded higher radiation leakage, which potentially contributed to the out-of-field radiation dose.
Collapse
Affiliation(s)
- Puntiwa Oonsiri
- Radiation Oncology DivisionRadiology DepartmentKing Chulalongkorn Memorial HospitalThe Thai Red Cross SocietyBangkokThailand
| | - Chulee Vannavijit
- Radiation Oncology DivisionRadiology DepartmentKing Chulalongkorn Memorial HospitalThe Thai Red Cross SocietyBangkokThailand
| | - Mananchaya Wimolnoch
- Radiation Oncology DivisionRadiology DepartmentKing Chulalongkorn Memorial HospitalThe Thai Red Cross SocietyBangkokThailand
| | - Sivalee Suriyapee
- Radiation Oncology DivisionRadiology DepartmentFaculty of MedicineChulalongkorn UniversityBangkokThailand
| | - Kitwadee Saksornchai
- Radiation Oncology DivisionRadiology DepartmentKing Chulalongkorn Memorial HospitalThe Thai Red Cross SocietyBangkokThailand
- Radiation Oncology DivisionRadiology DepartmentFaculty of MedicineChulalongkorn UniversityBangkokThailand
| |
Collapse
|
6
|
Peet SC, Kairn T, Lancaster CM, Trapp JV, Sylvander SR, Crowe SB. Measuring foetal dose from tomotherapy treatments. Med Dosim 2021; 46:342-346. [PMID: 33934977 DOI: 10.1016/j.meddos.2021.03.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 02/26/2021] [Accepted: 03/20/2021] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Treating pregnant women in the radiotherapy clinic is a rare occurrence. When it does occur, it is vital that the dose received by the developing embryo or foetus is understood as fully as possible. This study presents the first investigation of foetal doses delivered during helical tomotherapy treatments. Six treatment plans were delivered to an anthropomorphic phantom using a tomotherapy machine. These included treatments of the brain, unilateral and bilateral head-and-neck, chest wall, and upper lung. Measurements of foetal dose were made with an ionisation chamber positioned at various locations longitudinally within the phantom to simulate a variety of patient anatomies. All measurements were below the established limit of 100 mGy for a high risk of damage during the first trimester. The largest dose encountered was 75 mGy (0.125% of prescription dose). The majority of treatments with measurement positions less than 30 cm fell into the range of uncertain risk (50 - 100 mGy). All treatments with measurement positions beyond 30 cm fell into the low risk category (< 50 mGy). For the cases in this study, tomotherapy resulted in foetal doses that are at least on par with, if not significantly lower than, similar 3D conformal or intensity-modulated treatments delivered with other devices. Recommendations were also provided for estimating foetal doses from tomotherapy plans.
Collapse
Affiliation(s)
- Samuel C Peet
- Cancer Care Services, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland 4029, Australia; School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, GPO Box 2434, Brisbane, Queensland 4001, Australia.
| | - Tanya Kairn
- Cancer Care Services, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland 4029, Australia; School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, GPO Box 2434, Brisbane, Queensland 4001, Australia
| | - Craig M Lancaster
- Cancer Care Services, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland 4029, Australia
| | - Jamie V Trapp
- School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, GPO Box 2434, Brisbane, Queensland 4001, Australia
| | - Steven R Sylvander
- Cancer Care Services, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland 4029, Australia
| | - Scott B Crowe
- Cancer Care Services, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland 4029, Australia; School of Chemistry, Physics and Mechanical Engineering, Queensland University of Technology, GPO Box 2434, Brisbane, Queensland 4001, Australia
| |
Collapse
|
7
|
Rodrigues AJ, Waldrop AR, Suharwardy S, Druzin ML, Iv M, Ansari JR, Stone SA, Jaffe RA, Jin MC, Li G, Hayden-Gephart M. Management of brain tumors presenting in pregnancy: a case series and systematic review. Am J Obstet Gynecol MFM 2021; 3:100256. [PMID: 33451609 DOI: 10.1016/j.ajogmf.2020.100256] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 10/04/2020] [Accepted: 10/09/2020] [Indexed: 12/17/2022]
Abstract
Patients who present with brain tumors during pregnancy require unique imaging and neurosurgical, obstetrical, and anesthetic considerations. Here, we review the literature and discuss the management of patients who present with brain tumors during pregnancy. Between 2009 and 2019, 9 patients were diagnosed at our institution with brain tumors during pregnancy. Clinical information was extracted from the electronic medical records. The median age at presentation was 29 years (range, 25-38 years). The most common symptoms at presentation included headache (n=5), visual changes (n=4), hemiparesis (n=3), and seizures (n=3). The median gestational age at presentation was 20.5 weeks (range, 11-37 weeks). Of note, 8 patients (89%) delivered healthy newborns, and 1 patient terminated her pregnancy. In addition, 5 patients (56%) required neurosurgical procedures during pregnancy (gestational ages, 14-37 weeks) because of disease progression (n=2) or neurologic instability (n=3). There was 1 episode of postneurosurgery morbidity (pulmonary embolism [PE]) and no surgical maternal mortality. The median length of follow-up was 15 months (range, 6-45 months). In cases demonstrating unstable or progressive neurosurgical status past the point of fetal viability, neurosurgical intervention should be considered. The physiological and pharmacodynamic changes of pregnancy substantially affect anesthetic management. Pregnancy termination should be discussed and offered to the patient when aggressive disease necessitates immediate treatment and the fetal gestational age remains previable, although neurologically stable patients may be able to continue the pregnancy to term. Ultimately, pregnant patients with brain tumors require an individualized approach to their care under the guidance of a multidisciplinary team.
Collapse
Affiliation(s)
- Adrian J Rodrigues
- Departments of Neurosurgery, Stanford University School of Medicine, Stanford, CA
| | - Anne R Waldrop
- Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA
| | - Sanaa Suharwardy
- Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA
| | - Maurice L Druzin
- Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA
| | - Michael Iv
- Division of Neuroimaging and Neurointervention, Department of Radiology, Stanford University School of Medicine, Stanford, CA
| | - Jessica R Ansari
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA
| | - Sarah A Stone
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA
| | - Richard A Jaffe
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA
| | - Michael C Jin
- Departments of Neurosurgery, Stanford University School of Medicine, Stanford, CA
| | - Gordon Li
- Departments of Neurosurgery, Stanford University School of Medicine, Stanford, CA
| | | |
Collapse
|
8
|
Policicchio D, Doda A, Muggianu G, Dipellegrini G, Boccaletti R. Ethical and therapeutic dilemmas in glioblastoma management during pregnancy: Two case reports and review of the literature. Surg Neurol Int 2019; 10:41. [PMID: 31528379 PMCID: PMC6743686 DOI: 10.25259/sni-86-2019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Accepted: 02/04/2019] [Indexed: 01/01/2023] Open
Abstract
Introduction: There are no guidelines about the management of glioblastoma multiforme (GBM) during pregnancy: treatment of these patients presents therapeutic and ethical challenges. Case Description: Two patients, respectively, 28 years old at the 14th week of gestation with a thalamic GBM and 38 years old at the 28th week of gestation with fronto-mesial GBM. Patients and their relatives were deeply informed about the natural history of GBM and potential risks and benefits of surgery, radiotherapy (XRT), and chemotherapy (CTX) for both, mother and fetus. The first patient’s will was to preserve her fetus from any related, even minimal, risk of XRT, and CTX until safe delivery despite progression of GBM, accepting only surgery (tumor debulking and shunting of hydrocephalus). The second one asked to deliver the baby as soon as possible (despite the risks of prematurity) to receive the standard treatments of GBM. The two patients survived, respectively, 16 and 46 months after delivery. The first patient’s son is in good clinical conditions; the second one suffered problems linked to prematurity. Conclusions: Standard treatment of GBM in a pregnant woman could improve the mother’s survival but can expose the fetus to several potential risks. Ethically, relatives should understand that mother has anyway a poor prognosis and, at the same time, fetus prognosis depends on mother’s condition and therapy. It is not possible to warrant absence of risk for both. Considering the absence of guidelines and the relatively poor current data available about management of GBM in a pregnant woman, after a deep explanation of the situation, we think that the will of the mother and her relatives should prevail.
Collapse
Affiliation(s)
- Domenico Policicchio
- Department of Neurosurgery, Azienda Ospedaliero Universitaria di Sassari, Via Enrico De Nicola 1, 07100 Sassari, Italy
| | - Artan Doda
- Department of Neurosurgery, Azienda Ospedaliero Universitaria di Sassari, Via Enrico De Nicola 1, 07100 Sassari, Italy
| | - Giampiero Muggianu
- Department of Neurosurgery, Azienda Ospedaliero Universitaria di Sassari, Via Enrico De Nicola 1, 07100 Sassari, Italy
| | - Giosuè Dipellegrini
- Department of Neurosurgery, Azienda Ospedaliero Universitaria di Sassari, Via Enrico De Nicola 1, 07100 Sassari, Italy
| | - Riccardo Boccaletti
- Department of Neurosurgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
| |
Collapse
|
9
|
Rosen A, Anderson V, Bercovici E, Laperriere N, D'Souza R. Brainstem gliomas in pregnancy: a systematic review†. J Matern Fetal Neonatal Med 2019; 33:2841-2851. [PMID: 30563399 DOI: 10.1080/14767058.2018.1560410] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Introduction: Although brainstem gliomas are a rare group of neoplasias, when they affect pregnant women, there can be challenges with diagnosis and management. This study describes a case of brainstem glioma diagnosed in pregnancy and systematically reviews the literature on brainstem gliomas in pregnancy to provide guidance for management.Material and methods: We searched five databases from inception until October 2016 using subject headings and keywords related to pregnancy and brainstem glioma, and included original research articles that described pregnancy outcomes in women with brainstem glioma. Data extraction and quality assessment using the Joanna Briggs Institute Critical Appraisal Checklist for case reports were performed in duplicate. Outcomes were reported as proportions. The study protocol was registered with the Prospero International Prospective Register of Systematic Reviews (CRD42017060196).Results: We screened 2737 titles and abstracts, and 89 full-texts. Twelve articles describing 17 pregnancies in 16 women were included in the analysis. The median gestational age at presentation was 23 weeks. All but one case presented with neurologic deficit. Magnetic resonance (MRI) imaging conclusively diagnosed all cases. Surgical tumor resection (n = 4) and radiation therapy (n = 3) were successfully undertaken during pregnancy. There were no reported sequelae of maternal oncological management on neonatal wellbeing. Maternal mortality was high (8/16, 50%) both during (n = 5) and within 4 weeks (n = 3) of pregnancy. Pregnancy losses included one pregnancy termination and four miscarriages (associated with maternal mortality). Of the 12 live-born babies, five were premature. Two of these were the result of spontaneous preterm labor and three were delivered prematurely to facilitate glioma management. There was one case of fetal growth restriction.Conclusions: Although the symptoms of brainstem gliomas often mimic those commonly encountered in pregnancy, neurologic deficits warrant urgent investigation. MRI is the diagnostic modality of choice in pregnancy. Brainstem gliomas are associated with high maternal mortality and appropriate management, including surgical tumor resection and radiation therapy, should not be delayed on account of pregnancy. Pregnancy outcomes are favorable although there is a risk of preterm birth.Key messageBrainstem gliomas are associated with high maternal mortality and timely diagnosis using magnetic resonance imaging and treatment including surgical resection and radiation therapy should not be delayed during pregnancy. Pregnancy outcomes are generally favorable except for risk of preterm birth.
Collapse
Affiliation(s)
- Adam Rosen
- Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Canada.,Faculty of Medicine, University of Toronto, Toronto, Canada
| | | | - Eduard Bercovici
- Division of Neurology, Department of Medicine, Toronto Western Hospital, Krembil Neuroscience Centre, University of Toronto, Toronto, Canada
| | - Normand Laperriere
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - Rohan D'Souza
- Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, University of Toronto, Toronto, Canada
| |
Collapse
|
10
|
Orlandi E, Zonca G, Pignoli E, Stucchi C, Borroni M, Collini P, Cantù G, Casali PG, Grosso F, Cerrotta A, Fallai C, Olmi P. Postoperative Radiotherapy for Synovial Sarcoma of the Head and Neck during Pregnancy: Clinical and Technical Management and Fetal Dose Estimates. TUMORI JOURNAL 2018; 93:45-52. [PMID: 17455871 DOI: 10.1177/030089160709300109] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background In vivo and phantom dosimetry is reported to estimate the fetal dose and evaluate the effectiveness of a special shielding device to reduce fetal exposure in a woman undergoing postoperative radiation therapy for synovial oral cavity sarcoma at the 30th week of pregnancy. Methods In vivo measurements were performed by placing thermoluminescent dosimeters on 3 points for fetal dose estimation: uterine fundus, umbilicus and pubis. A Rando anthropomorphic phantom was used to simulate radiotherapy. We also performed off-axis dose measurements for wedged beams to estimate the dose contribution of this accessory used in the treatment. Results The special shielding device reduced the fetal dose by 70% on average, despite the presence of wedges, which increased the dose by a factor of about 2.5. Before delivery the patient received 48 Gy, and from the in vivo measurements a fetal dose of 8.5, 1.7 and 0.7 cGy was estimated to the uterine fundus, umbilicus and pubis, respectively. Conclusions Pre-treatment simulation in the same irradiation conditions is the only reliable approach to predict the fetal dose. By using a special shielding device, radiotherapy can be optimized while keeping the fetal exposure below the risk of deterministic damage.
Collapse
Affiliation(s)
- Ester Orlandi
- Department of Radiation Oncology I, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Mazonakis M, Damilakis J. Estimation and reduction of the radiation dose to the fetus from external-beam radiotherapy. Phys Med 2017; 43:148-152. [DOI: 10.1016/j.ejmp.2017.09.130] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 07/18/2017] [Accepted: 09/17/2017] [Indexed: 01/18/2023] Open
|
12
|
Paulsson AK, Braunstein S, Phillips J, Theodosopoulos PV, McDermott M, Sneed PK, Ma L. Patient-Specific Fetal Dose Determination for Multi-Target Gamma Knife Radiosurgery: Computational Model and Case Report. Cureus 2017; 9:e1527. [PMID: 28975062 PMCID: PMC5621780 DOI: 10.7759/cureus.1527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
A 42-year-old woman at 29 weeks gestation via in vitro fertilization who presented with eight metastatic brain lesions received Gamma Knife stereotactic radiosurgery (GKSRS) at our institution. In this study, we report our clinical experience and a general procedure of determining the fetal dose from patient-specific treatment plans and we describe quality assurance measurements to guide the safe practice of multi-target GKSRS of pregnant patients. To estimate fetal dose pre-treatment, peripheral dose-to-focal dose ratios (PFRs) were measured in a phantom at the distance approximating the fundus of uterus. Post-treatment, fetal dose was calculated from the actual patient treatment plan. Quality assurance measurements were carried out via the extrapolation dosimetry method in a head phantom at increasing distances along the longitudinal axis. The measurements were then empirically fitted and the fetal dose was extracted from the curve. The computed and measured fetal dose values were compared with each other and associated radiation risk was estimated. Based on low estimated fetal dose from preliminary phantom measurements, the patient was accepted for GKSRS. Eight brain metastases were treated with prescription doses of 15-19 Gy over 143 min involving all collimator sizes as well as composite sector mixed shots. Direct fetal dose computation based on the actual patient’s treatment plan estimated a maximum fetal dose of 0.253 cGy, which was in agreement with surface dose measurements at the level of the patient’s uterine fundus during the actual treatment. Later phantom measurements also estimated fetal dose to be in the range of 0.21-0.28 cGy (dose extrapolation curve R2 = 0.998). Using the National Council on Radiation Protection and Measurements (NCRP) population-based model, we estimate the fetal risk of secondary malignancy, which is the primary toxicity after 25 weeks gestation, to be less than 0.01%. Of note, the patient delivered the baby via scheduled cesarean section at 36 weeks without complications attributable to the GKSRS procedure. GKSRS of multiple brain metastases was demonstrated to be safe and feasible during pregnancy. The applicability of a general patient-specific fetal dose determination method was also demonstrated for the first time for such a treatment.
Collapse
Affiliation(s)
| | | | | | | | - Michael McDermott
- Department of Neurological Surgery, University of California, San Francisco
| | | | - Lijun Ma
- Radiation Oncology, University of California, San Francisco
| |
Collapse
|
13
|
Umehara T, Okita Y, Nonaka M, Kanemura Y, Kodama Y, Mano M, Nakajima S, Fujinaka T. A case of pilocytic astrocytoma requiring tumor resection during pregnancy. Mol Clin Oncol 2016; 4:567-570. [PMID: 27073664 DOI: 10.3892/mco.2016.773] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Accepted: 02/03/2016] [Indexed: 11/05/2022] Open
Abstract
Low-grade glioma (LGG) is often encountered in relatively young individuals, including women of childbearing age. Notably, case series describing pregnant women with LGG have been reported in the literature. The present study reported a case of pilocytic astrocytoma (PA) requiring tumor resection during pregnancy. The patient had a history of γ-knife radiotherapy for a brainstem tumor 17 years previously. The histological diagnosis was unclear. The tumor had remained stable following radiosurgery for 17 years, including during her first pregnancy. However, rapid tumor growth around the fourth ventricle occurred at week 25 of her second pregnancy. Therefore, an urgent tumor resection was performed despite the pregnancy. Partial resection was performed since the tumor had infiltrated the brainstem. The histological diagnosis was PA. The residual tumor volume decreased gradually following the delivery. Immunostaining of the tumor for the expression of progesterone receptor revealed focal staining. It is possible that reproductive factors, including specific hormonal changes during pregnancy, affected the tumor growth. The present study described this rare case of PA, which exhibited rapid growth and required urgent surgery during pregnancy.
Collapse
Affiliation(s)
- Toru Umehara
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Yoshiko Okita
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Masahiro Nonaka
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Yonehiro Kanemura
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan; Division of Regenerative Medicine, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Yoshinori Kodama
- Department of Central Laboratory and Surgical Pathology, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Masayuki Mano
- Department of Central Laboratory and Surgical Pathology, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Shin Nakajima
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| | - Toshiyuki Fujinaka
- Department of Neurosurgery, Osaka National Hospital, National Hospital Organization, Osaka 540-0006, Japan
| |
Collapse
|
14
|
Lefebvre L, Doyeux K, Linca S, Challand T, Hanzen C. [Radiotherapy of a glioma in a pregnant woman: evaluation of the foetal dose in conformational 3D or intensity-modulated]. Cancer Radiother 2014; 18:763-6. [PMID: 25451673 DOI: 10.1016/j.canrad.2014.07.158] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2014] [Revised: 06/23/2014] [Accepted: 07/02/2014] [Indexed: 10/24/2022]
Abstract
The purpose was to assess three treatments planning techniques including one in intensity-modulated radiation therapy (IMRT) for cerebral irradiation of pregnant woman, in order to limit the dose delivered to the foetus. The treatment provided was 60 Gy to the planning target volume. Estimated foetal dose was measured using an anthropomorphic phantom, on the upper and middle part of the uterus. The first plan consisted in four beams in conformational technique delivered from a Varian accelerator with a 120 leaves collimator, the second one used non-coplanar fields and the third one assessed IMRT. With the conformational technique, the dose at the upper part of the uterus was 8.3 mGy and 6.3 mGy at the middle part. The dose delivered to the foetus was higher with the non-coplanar fields. In IMRT, the dose at the upper part of the uterus was 23.8 mGy and 14.3 mGy at the middle part. The three plans used 6 MV X-rays. Because of the use of leaves and non-coplanar fields, IMRT does not seem to be the optimal technique for the treatment of pregnant woman. However, the dose delivered to the foetus remains low and below the dose of 100 mGy recommended by the International Commission of Radiological Protection. It seems possible to consider the use of this technique for a better sparing of organs at risk for the mother.
Collapse
Affiliation(s)
- L Lefebvre
- Département de radiothérapie, centre Henri-Becquerel, rue d'Amiens, 76038 Rouen cedex 1, France
| | - K Doyeux
- Département de radiothérapie, centre Henri-Becquerel, rue d'Amiens, 76038 Rouen cedex 1, France
| | - S Linca
- Département de radiothérapie, centre Henri-Becquerel, rue d'Amiens, 76038 Rouen cedex 1, France
| | - T Challand
- Département de radiothérapie, centre Henri-Becquerel, rue d'Amiens, 76038 Rouen cedex 1, France
| | - C Hanzen
- Département de radiothérapie, centre Henri-Becquerel, rue d'Amiens, 76038 Rouen cedex 1, France.
| |
Collapse
|
15
|
Horowitz DP, Wang TJC, Wuu CS, Feng W, Drassinower D, Lasala A, Pieniazek R, Cheng S, Connolly EP, Lassman AB. Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy. J Neurooncol 2014; 120:405-9. [PMID: 25096798 DOI: 10.1007/s11060-014-1565-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 07/21/2014] [Indexed: 10/25/2022]
Abstract
We examined the fetal dose from irradiation of glioblastoma during pregnancy using intensity modulated radiation therapy (IMRT), and describe fetal dose minimization using mobile shielding devices. A case report is described of a pregnant woman with glioblastoma who was treated during the third trimester of gestation with 60 Gy of radiation delivered via a 6 MV photon IMRT plan. Fetal dose without shielding was estimated using an anthropomorphic phantom with ion chamber and diode measurements. Clinical fetal dose with shielding was determined with optically stimulated luminescent dosimeters and ion chamber. Clinical target volume (CTV) and planning target volume (PTV) coverage was 100 and 98 % receiving 95 % of the prescription dose, respectively. Normal tissue tolerances were kept below quantitative analysis of normal tissue effects in the clinic (QUANTEC) recommendations. Without shielding, anthropomorphic phantom measurements showed a cumulative fetal dose of 0.024 Gy. In vivo measurements with shielding in place demonstrated a cumulative fetal dose of 0.016 Gy. The fetal dose estimated without shielding was 0.04 % and with shielding was 0.026 % of the target dose. In vivo estimation of dose equivalent received by the fetus was 24.21 mSv. Using modern techniques, brain irradiation can be delivered to pregnant patients in the third trimester with very low measured doses to the fetus, without compromising target coverage or normal tissue dose constraints. Fetal dose can further be reduced with the use of shielding devices, in keeping with the principle of as low as reasonably achievable.
Collapse
Affiliation(s)
- David P Horowitz
- Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Zwinkels H, Dörr J, Kloet F, Taphoorn MJB, Vecht CJ. Pregnancy in women with gliomas: a case-series and review of the literature. J Neurooncol 2013; 115:293-301. [DOI: 10.1007/s11060-013-1229-9] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2013] [Accepted: 08/10/2013] [Indexed: 11/28/2022]
|
18
|
Cancer in pregnancy. Part II: treatment options of breast and other non-gynecological malignancies. Arch Gynecol Obstet 2011; 284:1481-94. [DOI: 10.1007/s00404-011-2059-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2011] [Accepted: 08/02/2011] [Indexed: 12/17/2022]
|
19
|
Manohara S, Hanagodimath S, Gerward L. Energy absorption buildup factors for thermoluminescent dosimetric materials and their tissue equivalence. Radiat Phys Chem Oxf Engl 1993 2010. [DOI: 10.1016/j.radphyschem.2010.01.002] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Lew PS, Tan WC, Tan WK, Tan HK. Dilemmas in Management of Brain Tumours in Pregnancy. ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE 2010. [DOI: 10.47102/annals-acadmedsg.v39n1p64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
21
|
Luis SA, Christie DRH, Kaminski A, Kenny L, Peres MH. Pregnancy and radiotherapy: Management options for minimising risk, case series and comprehensive literature review. J Med Imaging Radiat Oncol 2009; 53:559-68. [DOI: 10.1111/j.1754-9485.2009.02124.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Karaçam SC, Güralp OS, Oksüz DC, Koca A, Cepni I, Cepni K, Bese N. The investigation of fetal doses in mantle field irradiation. RADIATION PROTECTION DOSIMETRY 2009; 133:165-170. [PMID: 19299479 DOI: 10.1093/rpd/ncp034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
To determine clinically the fetal dose from irradiation of Hodgkin's disease during pregnancy and to quantify the components of fetal dose using phantom measurements. The fetal dose was measured with phantom measurements using thermoluminescent dosemeters (TLDs). Phantom measurements were performed by simulating the treatment conditions on an anthropomorphic phantom. TLDs were placed on the phantom 41, 44, 46.5 and 49.5 cm from the centre of the treatment field. Two TLDs were placed on the surface of the phantom. The estimated total dose to all the TLDs ranged from 8.8 to 13.2 cGy for treatment with (60)Co and from 8.2 to 11.8 cGy for 4 MV photons. It was concluded that the doses in different sections were evaluated to investigate dose changes in different points and depths of fetal tissues in phantom. Precise planning and the use of supplemental fetal shielding may help reduce fetal exposure.
Collapse
Affiliation(s)
- Songül Cavdar Karaçam
- Department of Radiation Oncology, Cerrahpaşa Medical Faculty, University of Istanbul, Istanbul, Turkey.
| | | | | | | | | | | | | |
Collapse
|
23
|
Cheung EJ, Wagner H, Botti JJ, Fedok F, Goldenberg D. Advanced Oral Tongue Cancer in a 22-Year-Old Pregnant Woman. Ann Otol Rhinol Laryngol 2009; 118:21-6. [DOI: 10.1177/000348940911800104] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives: Oral squamous cell carcinoma generally occurs in older men and is associated mostly with tobacco and alcohol as the primary risk factors. The incidence of oral squamous cell carcinoma in younger patients has increased. We report a case of a young woman, 25 weeks pregnant, who presented with stage IV carcinoma of the oral tongue. Methods: The following is a case presentation and literature review. Results: The patient presented with T4 N3 M0 oral tongue cancer. A team consisting of a head and neck surgeon, a radiation oncologist, a medical oncologist, and a maternal-fetal medicine specialist was assembled. The patient initially refused surgery. Chemotherapy was initiated until 32 weeks' gestation. After an infant boy was delivered via cesarean section, the patient began concurrent irradiation and chemotherapy, which induced complete regression of the primary tongue neoplasm with a partial response of the neck nodes. The patient underwent bilateral neck dissection followed by hemiglossectomy for recurrence. Conclusions: Management of advanced oral carcinoma in pregnancy presents a unique set of challenges. Few studies have described chemotherapy and radiotherapy during pregnancy, and long-term results are needed. Care must be taken to balance appropriate and adequate treatment of disease and to ensure the safety of the patient and the fetus.
Collapse
|
24
|
Josipović M, Nyström H, Kjaer-Kristoffersen F. IMRT in a pregnant patient: how to reduce the fetal dose? Med Dosim 2008; 34:301-10. [PMID: 19854389 DOI: 10.1016/j.meddos.2008.11.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2008] [Revised: 11/26/2008] [Accepted: 11/27/2008] [Indexed: 11/15/2022]
Abstract
The purpose of our study was to find a solution for fetal dose reduction during head-and-neck intensity modulated radiation therapy (IMRT) of a pregnant patient. The first step was optimization of the IMRT treatment plan with as few monitor units (MUs) as possible, while maintaining an acceptable dose distribution. The peripheral dose originating from the final IMRT plan was measured at distances reaching from the most proximal to the most distal fetal position, along the accelerator's longitudinal axis, using an anthropomorphic phantom extended with water-equivalent plastic. The measured peripheral dose was divided into leakage, and internal and collimator scatter, to find the degree to which each component influences the peripheral dose to build an appropriate shield. Collimator scatter was the greatest contributor to the peripheral dose throughout the range of the growing fetus. A shield was built and placed beneath the accelerator head, extending caudally from the field edge, to function as an extra collimator jaw. This shield reduced the fetal dose by a factor of 3.5. The peripheral dose components were also measured for simple rectangular fields and also here the collimator scatter was the greatest contributor to the peripheral dose. Therefore, the shielding used for the IMRT treatment of our patient could also be used when shielding in conventional radiotherapy. It is important for a radiation therapy department to be prepared for treatment of a pregnant patient to shield the fetus efficiently.
Collapse
Affiliation(s)
- Mirjana Josipović
- Department of Radiation Physics, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark.
| | | | | |
Collapse
|
25
|
Marchesi V, Graff P, Noel A, Beckendorf V, Peiffert D. Optimisation et évaluation de la dose fœtale pendant une radiothérapie de la parotide droite. Cancer Radiother 2008; 12:380-4. [DOI: 10.1016/j.canrad.2008.03.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2007] [Revised: 03/14/2008] [Accepted: 03/27/2008] [Indexed: 11/16/2022]
|
26
|
Kry SF, Price M, Followill D, Mourtada F, Salehpour M. The use of LiF (TLD-100) as an out-of-field dosimeter. J Appl Clin Med Phys 2007; 8:169-175. [PMID: 18449155 PMCID: PMC5722615 DOI: 10.1120/jacmp.v8i4.2679] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2007] [Revised: 06/19/2007] [Accepted: 06/04/2007] [Indexed: 11/23/2022] Open
Abstract
The commonly used thermoluminescent dosimeter TLD-100 (Harshaw Chemical Company, Solon, OH) responds not only to photons and electrons, but also to neutrons that are produced during high-energy therapies. As a result, TLD-100 measurements outside of the treatment field are suspect when high-energy radiation is used. Although alternatives such as TLD-700 do not respond to neutrons, specialty dosimeters of this kind are expensive and are not routinely used in most clinics. In the current study, we examined the accuracy of TLD-100 in measuring the out-of-field photon dose as a function of treatment energy. To determine the accuracy of TLD-100 as compared with TLD-700, TLD-100 was irradiated outside of the treatment field by medical accelerators operated at 6, 10, 15, and 18 MV. In an effort to eliminate the response of TLD-100 to neutrons, TLD capsules were encased in varying thicknesses of cadmium foil (0.25 - 0.75 mm) before being irradiated at 18 MV. The out-of-field TLD-100 was found to be accurate at 6 MV and 10 MV, but to be substantially over-responsive at 15 MV and 18 MV (by up to 1063% relative to TLD-700). By wrapping the TLD-100 in up to 0.75 mm of cadmium, it was possible to drastically reduce (down to 39% on average) the over-response of the TLD-100; however, total removal of the over-responsiveness was not possible. Although TLD-100 is well suited for measuring out-of-field dose at energies as high as 10 MV, at higher energies (15 MV or greater), this dosimeter over-responds substantially and should not be used. Although encasing the TLD in cadmium minimized over-response to a degree, the reduction was not sufficient to make TLD-100 viable for measuring out-of-field dose at high treatment energies.
Collapse
Affiliation(s)
- Stephen F Kry
- Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A
| | - Michael Price
- Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A
| | - David Followill
- Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A
| | - Firas Mourtada
- Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A
| | - Mohammad Salehpour
- Department of Radiation Physics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A
| |
Collapse
|
27
|
Moreau MV, Brunaud C, Bologna S, Marchesi V, Hoffstetter S, Peiffert D. [High fetal irradiation: about one pregnant woman receiving infradiaphragmatic radiotherapy for Hodgkin lymphoma]. Cancer Radiother 2007; 11:495-9. [PMID: 17719816 DOI: 10.1016/j.canrad.2007.07.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Revised: 07/11/2007] [Accepted: 07/24/2007] [Indexed: 10/22/2022]
Abstract
We report the case of a 19-year-old young woman for whom was discovered a pregnancy at the end of the irradiation for a Hodgkin lymphoma (stage IV bone Bb), initially treated by chemotherapy. The radiotherapy delivered 36 Gy in infra-diaphragmatic volumes (lombo-aortic, spleen, L5), beginning in a pregnant patient for less than 4 amenorrhea weeks. The calculated received fetal dose (literature data, measurement with software TPS, measurement on phantom) is high: it's between 2.8 and 5 Gy. With a current follow-up of 4 years since the radiotherapy's end, the patient is in complete remission and her child presents with a normal development for the age, in spite of the infradiaphragmatic irradiation.
Collapse
Affiliation(s)
- M V Moreau
- Service de radiothérapie, centre Alexis-Vautrin, 54511 Vandoeuvre-lès-Nancy, France.
| | | | | | | | | | | |
Collapse
|
28
|
Kry SF, Starkschall G, Antolak JA, Salehpour M. Evaluation of the accuracy of fetal dose estimates using TG-36 data. Med Phys 2007; 34:1193-7. [PMID: 17500450 DOI: 10.1118/1.2710332] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The American Association of Physicists in Medicine Radiation Therapy Committee Task Group 36 report (TG-36) provides guidelines for managing radiation therapy of pregnant patients. Included in the report are data that can be used to estimate the dose to the fetus. The purpose of this study is to evaluate the accuracy of these fetal dose estimates as compared to clinically measured values. TG-36 calculations were performed and compared with measurements of the fetal dose made in vivo or in appropriately-designed phantoms. Calculation and measurement data was collected for eight pregnant patients who underwent radiation therapy at the MD Anderson Cancer Center as well as for several fetal dose studies in the literature. The maximum measured unshielded fetal dose was 47 cGy, which was 1.5% of the prescription dose. For all cases, TG-36 calculations and measured fetal doses differed by up to a factor of 3--the ratio of the calculated to measured dose ranged from 0.34 to 2.93. On average, TG-36 calculations underestimated the measured dose by 31%. No significant trends in the relationship between the calculated and measured fetal doses were found based on the distance from, or the size of, the treatment field.
Collapse
Affiliation(s)
- Stephen F Kry
- Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | |
Collapse
|
29
|
Bradley B, Fleck A, Osei EK. Normalized data for the estimation of fetal radiation dose from radiotherapy of the breast. Br J Radiol 2006; 79:818-27. [PMID: 16854965 DOI: 10.1259/bjr/16416346] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
There can be several reasons why a pregnant patient may receive a radiological examination. It could have been a planned exposure, or the exposure might have resulted from an emergency when a thorough evaluation of pregnancy was impractical. Sometimes the pregnancy was unsuspected at the time of the examination and, with younger women being diagnosed with breast cancer, the likelihood of this will increase in radiotherapy departments. Whatever the reason, when presented with a pregnant patient who has received a radiological examination involving ionizing radiation, the dose to the fetus should be assessed based on the patient's treatment plan. However, a major source of uncertainty in the estimation of fetal absorbed dose is the influence of fetal size and position as these change with gestational age. Consequently, dose to the fetus is related to gestational age. Various studies of fetal dose during pregnancy have appeared in the literature. Whilst these papers contain many useful data for estimating fetal dose, they usually contain limited data regarding the depth and size of the fetus within the maternal uterus. We have investigated doses to the fetus from radiation therapy of the breast of a pregnant patient using an anthropomorphic phantom. Normalized data for estimating fetal doses that takes into account the fetal size (gestational age: 8-20 weeks post-conception) and depth within the maternal abdomen (4-16 cm) for different treatment techniques have been provided. The data indicate that fetal dose is dependent on both depth within the maternal abdomen and gestational age, and hence these factors should always be considered when estimating fetal dose. The data show that fetal dose can be underestimated up to about 10% or overestimated up to about 30% if the dose to the uterus is assumed instead of the actual fetal dose. It can also be underestimated up to about 23% or overestimated up to about 12% if a mean depth of 9 cm is assumed, instead of using the actual depth of the fetus within the maternal abdomen. Multi-segments sMLC technique showed consistently lower fetal doses compared with all the wedged plans employed.
Collapse
Affiliation(s)
- B Bradley
- Department of Systems Design Engineering, University of Waterloo, 200 University Avenue West, Waterloo, Ontario, Canada
| | | | | |
Collapse
|
30
|
Sharma DS, Deshpande SS, Phurailatpam RD, Deshpande DD, Shrivastava SK, Dinshaw KA. Peripheral dose from uniform dynamic multileaf collimation fields: implications for sliding window intensity-modulated radiotherapy. Br J Radiol 2006; 79:331-5. [PMID: 16585727 DOI: 10.1259/bjr/16208090] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The increase in the number of monitor units in sliding window intensity-modulated radiotherapy, compared with conventional techniques for the same target dose, may lead to an increase in peripheral dose (PD). PD from a linear accelerator was measured for 6 MV X-ray using 0.6 cm3 ionization chamber inserted at 5 cm depth into a 35 cm x 35 cm x 105 cm plastic water phantom. Measurements were made for field sizes of 6 cm x 6 cm, 10 cm x 10 cm and 14 cm x 14 cm, shaped in both static and dynamic multileaf collimation (DMLC) mode, employing strip fields of fixed width 0.5 cm, 1.0 cm, 1.5 cm, and 2.0 cm, respectively. The effect of collimator rotation and depth of measurement on peripheral dose was investigated for 10 cm x 10 cm field. Dynamic fields require 2 to 14 times the number of monitor units than does a static open field for the same dose at the isocentre, depending on strip field width and field size. Peripheral dose resulting from dynamic fields manifests two distinct regions showing a crest and trough within 30 cm from the field edge and a steady exponential fall beyond 30 cm. All dynamic fields were found to deliver a higher PD compared with the corresponding static open fields, being highest for smallest strip field width and largest field size; also, the percentage increase observed was highest at the largest out-of-field distance. For 6 cm x 6 cm field, dynamic fields with 0.5 cm and 2 cm strip field width deliver PDs 8 and 2 times higher than that of the static open field. The corresponding factors for 14 cm x 14 cm field were 15 and 6, respectively. The factors by which PD for DMLC fields increase, relative to jaws-shaped static fields for out-of-field distance beyond 30 cm, are almost the same as the corresponding increases in the number of monitor units. Reductions of 20% and 40% in PD were observed when the measurements were done at a depth of 10 cm and 15 cm, respectively. When the multileaf collimator executes in-plane (collimator 90 degrees) motion, peripheral dose decreases by as much as a factor of 3 compared with cross-plane data. The knowledge of PD from DMLC field is necessary to estimate the increase in whole-body dose and the likelihood of radiation induced secondary malignancy.
Collapse
Affiliation(s)
- D S Sharma
- Department of Medical Physics, Tata Memorial Hospital, Dr. Ernest Borges Marg, Parel, Mumbai, 400 012, India
| | | | | | | | | | | |
Collapse
|
31
|
Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P. Prise en charge des gliomes malins découverts au cours d’une grossesse. Rev Neurol (Paris) 2006; 162:322-9. [PMID: 16585887 DOI: 10.1016/s0035-3787(06)75018-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Glioma is seldom diagnosed during pregnancy. In this situation management presents difficult problems for both neuro-oncologists and obstetricians. We report four cases and discuss the management of this unusual situation. CASE REPORT The first patient was admitted to hospital at 29 weeks' gestation because of a generalized seizure and a right hemiparesis. MRI showed a left fronto-insular lesion. A stereotactic biopsy was obtained and revealed an anaplastic oligodendroglioma. With corticosteroids the patient remained stable until cesarean delivery at 36 weeks. In post-partum additional treatment with chemotherapy was started. The second patient was hospitalized at 26 weeks' gestation because of cranial hypertension, right hemiparesis and aphasia. MRI showed an important left fronto-parietal lesion. Partial resection was performed at 28 weeks. Histology revealed a glioblastoma multiforme. With corticosteroids the patient remained stable until cesarean delivery at 33 weeks. In post-partum additional treatment with radiotherapy and chemotherapy was started. The third patient was admitted to the hospital at 12 weeks' gestation because of cranial hypertension. MRI showed a left frontal lesion. A subtotal resection was done at 13 weeks. Histology revealed a glioblastoma multiforme. Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided. Afterwards additional treatment with radiotherapy and chemotherapy was started. The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma. A posteriori it was discovered that the patient was at 4 months' gestation during this treatment. Cesarean delivery was done at 36 weeks. The child was normal at birth and is still in good health 5 years later. CONCLUSION The management of gliomas diagnosed during pregnancy should not be different from the standard management of gliomas in young non-pregnant adults. Pregnant women because of their young age can have a long survival. Their pregnancy should not prevent them from receiving the best treatment for their glioma. Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires. Generally speaking, surgical resection of high-grade gliomas should not be delayed during pregnancy. Progress in anesthesia and neurosurgery have greatly reduced the risks for the foetus. After delivery, if the delay between surgery and delivery is too long it is possible to begin cerebral radiotherapy during pregnancy. After the first trimester of gestation this treatment can be given without any important risks for the child.
Collapse
MESH Headings
- Abortion, Therapeutic
- Adrenal Cortex Hormones/therapeutic use
- Adult
- Algorithms
- Anesthesia, General
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Carbamazepine/therapeutic use
- Carmustine/administration & dosage
- Case Management
- Cesarean Section
- Chemotherapy, Adjuvant
- Cranial Irradiation
- Craniotomy
- Dacarbazine/analogs & derivatives
- Dacarbazine/therapeutic use
- Female
- Frontal Lobe
- Glioblastoma/drug therapy
- Glioblastoma/radiotherapy
- Glioblastoma/surgery
- Glioblastoma/therapy
- Humans
- Infant, Newborn
- Intracranial Hypertension/etiology
- Magnetic Resonance Imaging
- Male
- Neoplasm Recurrence, Local
- Nitrosourea Compounds/administration & dosage
- Nitrosourea Compounds/therapeutic use
- Organophosphorus Compounds/administration & dosage
- Organophosphorus Compounds/therapeutic use
- Paresis/drug therapy
- Paresis/etiology
- Prednisolone/therapeutic use
- Pregnancy
- Pregnancy Complications, Neoplastic/drug therapy
- Pregnancy Complications, Neoplastic/radiotherapy
- Pregnancy Complications, Neoplastic/surgery
- Pregnancy Complications, Neoplastic/therapy
- Prenatal Exposure Delayed Effects
- Radiotherapy, Adjuvant
- Remission Induction
- Supratentorial Neoplasms/drug therapy
- Supratentorial Neoplasms/radiotherapy
- Supratentorial Neoplasms/surgery
- Supratentorial Neoplasms/therapy
- Temozolomide
- Temporal Lobe
Collapse
Affiliation(s)
- F Ducray
- Service de Neurologie B, Hôpital Neurologique Pierre-Wertheimer, Lyon
| | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Radiotherapy during pregnancy might cause harm to the developing fetus. Generally, pregnant women with malignant diseases are advised to delay radiotherapy until after delivery. However, this advice is not based on knowledge of the risks of radiation to the unborn child. In general, the expected radiation effects, such as mental retardation and organ malformations probably only arise above a threshold dose of 0.1-0.2 Gy. This threshold dose is not generally reached with curative radiotherapy during pregnancy, provided that tumours are located sufficiently far from the fetus and that precautions have been taken to protect the unborn child against leakage radiation and collimator scatter of the teletherapy machine; such precautions also reduce the risk of radiation-induced childhood cancer and leukaemia in the unborn child.
Collapse
|
33
|
Haba Y, Twyman N, Thomas SJ, Overton C, Dendy P, Burnet NG. Radiotherapy for Glioma During Pregnancy: Fetal Dose Estimates, Risk Assessment and Clinical Management. Clin Oncol (R Coll Radiol) 2004; 16:210-4. [PMID: 15191010 DOI: 10.1016/j.clon.2004.01.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Cancer in pregnancy is relatively uncommon, but constitutes a major problem. We report the measurement of scatter dose to the fetus and the estimated fetal risk from that exposure in an illustrative case of a patient, 20 weeks pregnant, with a grade 3 anaplastic astrocytoma. A clinical decision was made to withhold radiotherapy, if possible, until after delivery. Sequential magnetic resonance imaging (MRI) showed no progression during the pregnancy. In the event, she was managed conservatively until the successful completion of her pregnancy. In case radiotherapy was required, an estimation of the fetal risk was made. Phantom measurements were undertaken to assess the likely fetal dose. Film badges were used to estimate the scattered radiation energy. Measurements were made on a Varian 600C at 6 MV and Asea Brown Boveri (ABB) accelerator at 8 and 16 MV. Doses were measured at 30, 45 and 60 cm from the isocentre; the fetus was assumed to lie at about 60 cm and not closer than 45 cm from the isocentre. Estimated doses to the position of the fetus were lowest with the 6 MV Varian accelerator. Using this machine without additional abdominal shielding, the estimated dose on the surface at 45 cm from the tumour volume was 2.2 cGy for a tumour dose of 54 Gy; using the ABB accelerator, the dose varied between 49-59 cGy. The energy of scattered radiation was in the range 208-688 keV, so that additional shielding would be practical to further reduce the fetal dose. The risk of cancer up to the age of 15 years attributable to radiation is 1 in 1700 per cGy, of which half will be fatal (i.e. 1 in 3300 per cGy). A dose of 2.2 cGy adds a risk of fatal cancer by the age 15 years of only 1 in 1500. Because the addition of shielding might halve the fetal dose, this risk should be reduced to 1 in 3000. For comparison, the overall UK risk of cancer up to the age 15 years is 1 in 650. In conclusion, careful choice of linear accelerator for the treatment of a pregnant woman and the use of additional shielding is valuable, as this can dramatically affect fetal dose.
Collapse
Affiliation(s)
- Y Haba
- Oncology Centre, The Addenbrooke's Hospital, Cambridge, UK.
| | | | | | | | | | | |
Collapse
|
34
|
Moeckli R, Ozsahin M, Pache G, Valley JF, Mirimanoff RO, Azria D. Fetal dose reduction in head and neck radiotherapy of a pregnant woman. Z Med Phys 2004; 14:168-72. [PMID: 15462418 DOI: 10.1078/0939-3889-00215] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND AND PURPOSE A pregnant woman was referred for post-operative radiotherapy of a malignant schwannoma in the head and neck region. A best-treatment plan was devised in order to minimize the fetal dose. MATERIAL AND METHODS The fetal dose resulting from radiological examinations was determined according to international protocols, that resulting from radiotherapy was calculated according to Recommendation 36 of the American Association of Physicists in Medicine (AAPM) Task Group. Pre-treatment dosimetry was performed with an anthropomorphic phantom. Several alternative treatment plans were evaluated. The use of a multileaf collimator (MLC) and a virtual wedge (VW) was compared to cerrobend blocks (CB) and physical wedge (PW). In-vivo dosimetry was performed using a vaginal probe containing thermoluminescent dosimeters (TLD). RESULTS The total fetal dose resulting from diagnostic and radiotherapy procedures was estimated to be 36 mGy. The technique based on MLC and VW was elected for patient treatment. Measurements for this configuration resulted in afetal dose reduction of 82%. The shielding of the patient's abdomen further reduced the fetal dose by 42%. CONCLUSION The use of VW and MLC for the treatment of a pregnant woman is highly recommended. Each case should be individually studied with pre-treatment and in-vivo dosimetry.
Collapse
Affiliation(s)
- Raphaël Moeckli
- University Institute of Applied Radiophysics, Grand-Pré 1, 1007 Lausanne, Switzerland.
| | | | | | | | | | | |
Collapse
|
35
|
Sharma DS, Jalali R, Tambe CM, Deshpande DD. Effect of tertiary multileaf collimator (MLC) on foetal dose during three-dimensional conformal radiation therapy (3DCRT) of a brain tumour during pregnancy. Radiother Oncol 2004; 70:49-54. [PMID: 15036852 DOI: 10.1016/j.radonc.2003.10.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2003] [Revised: 09/18/2003] [Accepted: 10/09/2003] [Indexed: 11/24/2022]
Abstract
BACKGROUND AND PURPOSE The aim of this work was to measure the dose to foetus both in vivo and in vitro during three-dimensional conformal radiation therapy (3DCRT) in a pregnant patient with a pituitary adenoma. The study was then extended to assess the components contributing to the foetal dose such as collimator scatter, internal scatter, head leakage, wedge scatter and multileaf collimator (MLC) effect. PATIENTS AND METHODS A 30-year-old pregnant woman with a non-functioning pituitary macroadenoma was planned for 3DCRT with 6MV X-ray using four equally weighted MLC-shaped non-coplanar wedged portals. In vivo dosimetry was carried out using thermoluminescent (TL) phosphor powder, which was placed at different positions on the patient, corresponding to different locations in the uterus and also at external os. In vitro measurements were also performed on a simulated phantom using the same set-up parameters and beam arrangement to verify the in vivo measured dose. Experiments were carried out to measure the respective contributions of different components towards peripheral dose. RESULTS In vitro measured dose to foetus was found to be slightly more than that of in vivo measurement with a maximum of 0.044% of the prescribed dose of 45Gy, which corresponded to 0.0199+/-0.0008Gy. Thermoluminescence dosimeter (TLD) kept at the external os of the patient showed a dose of 0.031% of the prescribed dose. Among the various components of the peripheral dose (foetal dose) measured, head leakage was found to be the leading cause contributing 52%, followed by wedge scatter (31%), collimator scatter (14%) and internal scatter (13%). The use of MLC reduced not only the volume of normal brain irradiation as compared to open fields but also the peripheral dose by 10%. CONCLUSION Radiotherapy of brain tumours during pregnancy poses a unique clinical situation and decisions to deliver radiotherapy should be taken after detailed in vitro and in vivo dosimetric measurements. Our findings suggest that the beam arrangement using 3-4-fields generally used for 3DCRT of brain tumour with MLC for optimal coverage can be employed for pregnant patients even in early trimester. A possible increase in foetal dose from wedges to a large extent can be compensated with the use of MLC.
Collapse
Affiliation(s)
- Dayananda S Sharma
- Department of Medical Physics, Tata Memorial Hospital, Parel, Mumbai, India
| | | | | | | |
Collapse
|
36
|
Yu C, Jozsef G, Apuzzo MLJ, MacPherson DM, Petrovich Z. Fetal radiation doses for model C gamma knife radiosurgery. Neurosurgery 2003; 52:687-93; discussion 693. [PMID: 12590695 DOI: 10.1227/01.neu.0000048479.23069.24] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2002] [Accepted: 10/18/2002] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE To assess fetal radiation doses in a pregnant patient undergoing gamma knife stereotactic radiosurgery (GKRS) and to quantify the components of extracranial radiation doses by means of phantom measurements. METHODS A patient in her 25th week of pregnancy received GKRS with the Model C gamma knife for a solitary metastatic melanoma of the brain. A single isocenter with the 14-mm collimator and trunnions was used to deliver 20 Gy to the lesion defined to the 80% isodose line. Fetal radiation doses were assessed with phantom measurements before GKRS and then measured during GKRS. In addition, doses to the lateral canthi, thyroid, sternum, and pelvis were monitored with thermoluminescent dosimeters in 20 consecutive patients during their GKRS. Phantom measurements were also performed to identify extracranial radiation doses to these structures. RESULTS Fetal radiation doses were 0.31, 0.20, and 0.15 cGy to the top, middle, and bottom of the uterus, respectively. These approximately corresponded to 0.01% of the maximum tumor dose of 25 Gy. The mean extracranial doses in 20 patients were 36.9, 5.8, 3.3, and 0.6 cGy to the lateral canthi, thyroid, sternum, and pelvis, respectively. Phantom measurements supported the results obtained from the patient measurements and further refined estimates of doses to extracranial sites. These measurements were also compared with those of a previously reported study with the use of the Model U. CONCLUSION Measured radiation doses in a pregnant patient to extracranial sites, including those to the fetus, were very low. We think that GKRS is a safe treatment, particularly with the Model C, and could be recommended to carefully selected patients with brain metastases who are in the second and third trimester of pregnancy.
Collapse
Affiliation(s)
- Cheng Yu
- Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
| | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- Ron Swensen
- Department of Gynecology and Obstetrics, Loma Linda University School of Medicine, California 92354, USA.
| | | |
Collapse
|
38
|
Ioffe V, Hudes RS, Shepard D, Simard JM, Chin LS, Yu C. Fetal and ovarian radiation dose in patients undergoing gamma knife radiosurgery. SURGICAL NEUROLOGY 2002; 58:32-41; discussion 41. [PMID: 12361645 DOI: 10.1016/s0090-3019(02)00742-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
BACKGROUND It is difficult to estimate the fetal or ovarian radiation dosage for female patients undergoing Gamma Knife radiosurgery. Our goals are to determine the fetal and ovarian radiation dose at various distances from a cranial isocenter, to provide a reference for practitioners to estimate the fetal dose with respect to gestational age, and to identify the components of pelvic extracranial radiation. METHODS An anthropomorphic phantom and ion chamber were used to measure the dose at 50, 60, and 70 cm from a cranial isocenter and at three points within the transverse plane for the supine position. Each measurement consisted of a 5-minute exposure. Additional measurements were taken for four collimator sizes, the prone position, off-axis, and with one-half of all collimator holes plugged. RESULTS The values of the fetal and ovarian dose rates ranged from 0.27 cGy/min to 0.05 cGy/min based on distance from the isocenter. The fetal and ovarian dose can be up to 8.1 cGy for a 30-minute Gamma Knife treatment. The dose fell off more rapidly than predicted by the inverse square law. There was no dependence of fetal dose rate on collimator size. No advantage to the prone position could be shown. Leakage and collimator scatter are the main components of extracranial dose 50 to 70 cm from the isocenter. CONCLUSIONS The fetal and ovarian dose is a function of treatment time and distance from the isocenter. We recommend pregnancy status assessment in women of reproductive age and treatment plan design using large volume shots in order to minimize treatment time.
Collapse
Affiliation(s)
- Vladimir Ioffe
- Department of Radiation Oncology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21229, USA
| | | | | | | | | | | |
Collapse
|
39
|
Magné N, Marcié S, Pignol JP, Casagrande F, Lagrange JL. Radiotherapy for a solitary brain metastasis during pregnancy: a method for reducing fetal dose. Br J Radiol 2001; 74:638-41. [PMID: 11509400 DOI: 10.1259/bjr.74.883.740638] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
A patient presented during the second half of pregnancy with a solitary brain metastasis from lung cancer. This case shows that, using a new patient position, it is possible to shield the fetus efficiently. This new method consisted of whole brain irradiation with parallel pair treatment by lateral fields with the patient in a supine position with maximal neck extension. The dose to the fetus has been considerably reduced (0.3 cGy total dose) compared with previous techniques. The prescribed tumour dose was 30 Gy.
Collapse
Affiliation(s)
- N Magné
- Radiotherapy Department, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France
| | | | | | | | | |
Collapse
|
40
|
Kouvaris JR, Antypas CE, Sandilos PH, Plataniotis GA, Tympanides CN, Vlahos LJ. Postoperative tailored radiotherapy for locally advanced breast carcinoma during pregnancy: a therapeutic dilemma. Am J Obstet Gynecol 2000; 183:498-9. [PMID: 10942495 DOI: 10.1067/mob.2000.104842] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A 45-year-old woman with breast carcinoma was found to be pregnant during postoperative radiotherapy. The pregnancy was desired. We performed in vivo and phantom radiation dosimetry. No effects on the embryo or treatment disadvantages for the patient were expected. Thirty-six months post partum the baby is healthy and the mother is free of disease.
Collapse
Affiliation(s)
- J R Kouvaris
- Department of Radiology and Radiotherapy, University of Athens, Aretaieion Hospital, Greece
| | | | | | | | | | | |
Collapse
|
41
|
Tewari KS, Cappuccini F, Asrat T, Flamm BL, Carpenter SE, Disaia PJ, Quilligan EJ. Obstetric emergencies precipitated by malignant brain tumors. Am J Obstet Gynecol 2000; 182:1215-21. [PMID: 10819861 DOI: 10.1016/s0002-9378(00)70188-8] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Our goal was to present a case series of pregnancy-associated malignant brain tumors. STUDY DESIGN A review was conducted from 1978-1998 at 5 hospitals. RESULTS Ten women were diagnosed with a malignant brain tumor during pregnancy (n = 8) or post partum (n = 2). Patients diagnosed antenatally exhibited severe symptoms, manifest between 27 and 32 weeks' gestation. Six were emergently delivered of their infants because of maternal deterioration, and 2 were delivered electively in the early third trimester after documentation of fetal pulmonary maturity. There were 4 maternal deaths and 1 neonatal death; all of the other infants maintained viability. CONCLUSIONS Malignant brain tumors rarely occur in pregnancy. In contrast to reports that describe an indolent course, each of the 8 antenatal patients experienced a neurologic crisis. If symptoms are amenable to pharmacologic control, we advocate delivery in the early third trimester after documentation of fetal pulmonary maturity. To minimize temporal lobe or cerebellar herniation in neurologically unstable patients, a consideration should be made for cesarean delivery with the patient under general anesthesia, followed by immediate neurosurgical decompression.
Collapse
Affiliation(s)
- K S Tewari
- Department of Obstetrics and Gynecology and Surgical Pathology, University of California, Irvine Medical Center, Orange, CA, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Prado KL, Nelson SJ, Nuyttens JJ, Williams TE, Vanek KN. Clinical implementation of the AAPM Task Group 36 recommendations on fetal dose from radiotherapy with photon beams: a head and neck irradiation case report. J Appl Clin Med Phys 2000; 1:1-7. [PMID: 11674814 PMCID: PMC5726163 DOI: 10.1120/jacmp.v1i1.2650] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/1999] [Accepted: 12/15/1999] [Indexed: 11/23/2022] Open
Abstract
We present the results of our efforts in estimating and diminishing the fetal dose expected when a 29-year-old patient, 22 weeks pregnant, received external beam radiation therapy for a squamous cell carcinoma of the tongue. We explain our use of the information contained, and recommendations made, in the Report of the American Association of Physicists in Medicine Radiation Therapy Committee Task Group 36 [Med. Phys. 22, 63-82 (1995)]. We also explain our dose estimation, describe our validation measurements, and demonstrate the effectiveness of supplemental shielding. Consequently, this case report will serve as a guide to radiation oncologists and medical physicists who may encounter similar cases.
Collapse
Affiliation(s)
- Karl L. Prado
- Radiation Oncology DepartmentMedical University of South Carolina171 Ashley AvenueCharlestonSouth Carolina29425
| | - Stephen J. Nelson
- Radiation Oncology DepartmentMedical University of South Carolina171 Ashley AvenueCharlestonSouth Carolina29425
| | - Joost J. Nuyttens
- Radiation Oncology DepartmentMedical University of South Carolina171 Ashley AvenueCharlestonSouth Carolina29425
| | - Todd E. Williams
- Radiation Oncology DepartmentMedical University of South Carolina171 Ashley AvenueCharlestonSouth Carolina29425
| | - Kenneth N. Vanek
- Radiation Oncology DepartmentMedical University of South Carolina171 Ashley AvenueCharlestonSouth Carolina29425
| |
Collapse
|
43
|
Mutic S, Klein EE. A reduction in the AAPM TG-36 reported peripheral dose distributions with tertiary multileaf collimation. American Association of Physicists in Medicine Task Group 36. Int J Radiat Oncol Biol Phys 1999; 44:947-53. [PMID: 10386654 DOI: 10.1016/s0360-3016(99)00092-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
PURPOSE The American Association of Physicists in Medicine Task Group 36 (AAPM TG-36) data can be used to estimate peripheral dose (PD) distributions outside the primary radiation field. However, the report data apply to linear accelerators not equipped with tertiary multileaf collimators (MLCs). Peripheral dose distributions consist of internal scatter, collimation scatter, transmission through collimation, head leakage, and room scatter. Tertiary MLCs may significantly reduce the PD due to a reduction in collimation scatter, transmission through collimation, and head leakage. Measurements were performed on a multimodality linear accelerator, equipped with a tertiary MLC, to determine PD distributions as a function of energy, field size, distance from the primary radiation field edge, MLC position, and collimator orientation. METHODS AND MATERIALS Measurements were made using an ionization chamber embedded in a 20 x 40 x 120-cm3 water-equivalent plastic phantom with the secondary collimator and MLC settings of 10 x 10, 15 x 15, 20 x 20, 25 x 25 cm2, and with the MLC fully retracted. Data were taken along the longitudinal axis of the machine for 6 and 18 MV photons. Peripheral dose distributions were evaluated with the collimator set to 180 and 90 degrees. Rotation of the collimator allowed measurements parallel and orthogonal to the direction of motion of the MLC. RESULTS For both photon energies, peripheral doses measured on a MLC machine were lower than the TG-36 data. When the collimator is rotated by 90 degrees, placing the lower jaws and the MLC leaves along the plane of interest, PD was reduced by as much as a factor of three compared with PDs measured with the MLC fully retracted and the collimator rotated to 180 degrees. PDs measured with the MLC fully retracted and collimator rotated to 180 degrees were comparable to the TG-36 data. Measured PDs were lower when the MLC was used to shape the field than when the MLC was fully retracted. CONCLUSION A strategic orientation of the collimator with a tertiary MLC can reduce PD distributions by more than a factor of two. This decrease significantly lessens or eliminates the need for external lead shielding to reduce the critical organ dose. This method can be used even when Lipowitz metal blocking (such as for mantle fields) is used, with the MLC leaves oriented along the longitudinal plane.
Collapse
Affiliation(s)
- S Mutic
- Division of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, MO 63110, USA.
| | | |
Collapse
|
44
|
Yu C, Luxton G. TLD dose measurement: a simplified accurate technique for the dose range from 0.5 cGy to 1000 cGy. Med Phys 1999; 26:1010-6. [PMID: 10436903 DOI: 10.1118/1.598493] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A simplified TLD technique characterized by high precision and reproducibility of dose measurement is presented. One hundred eighty LiF TLD rods 1 mm diam x 3 mm length as obtained from the manufacturer were annealed for 1 h at 400 degrees C followed immediately by 2 h at 105 degrees C. After exposure to a dose of 1 Gy of 4 MV x rays, TLDs were annealed for 15 min at 105 degrees C, then read out. TLDs were then sorted into five groups, ranging from 26 to 50 rods each with approximately equal sensitivity after correcting for the drift in the sensitivity of the TLD reader during the readout session. Maintaining group identity, the TLDs were again annealed, irradiated and read out. Fewer than 10% of the TLDs were removed from each group because the corrected readings differed from the respective group mean by more than 3.5%. The standard deviation of the readout was approximately 1.5% within each group. The planchet heater was not flushed with nitrogen gas. Various tests were performed to assess the stability of the group sorting technique and the linearity of TLD dose response. After reannealing, five TLDs were randomly drawn from one of the presorted groups, and subjected to various dose of 4 MV radiation over the range from 0.5 to 1000 cGy. This resulted in an average readout standard deviation of 1.2%. Response per unit dose was almost flat over the range from 0.5 cGy to 100 cGy, and increased by 15% over the range from 100 cGy to 1000 cGy. TLD sensitivity was affected by the duration of the anneal, but was virtually independent of the various time delays between irradiation, prereadout anneal, and readout. The group annealing and sorting (GAS) procedure provides a simple, reliable, precise, convenient, and accurate method for TLD measurements.
Collapse
Affiliation(s)
- C Yu
- Department of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles 90033, USA
| | | |
Collapse
|
45
|
Mazonakis M, Damilakis J, Varveris H, Theoharopoulos N, Gourtsoyiannis N. A method of estimating fetal dose during brain radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:455-9. [PMID: 10760443 DOI: 10.1016/s0360-3016(99)00023-1] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To develop a simple method of estimating fetal dose during brain radiation therapy. METHODS AND MATERIALS An anthropomorphic phantom was modified to simulate pregnancy at 12 and 24 weeks of gestation. Fetal dose measurements were carried out using thermoluminescent dosimeters. Brain radiation therapy was performed with two lateral and opposed fields using 6 MV photons. Three sheets of lead, 5.1-cm-thick, were positioned over the phantom's abdomen to reduce fetal exposure. Linear and nonlinear regression analysis was used to investigate the dependence of radiation dose to an unshielded and/or shielded fetus upon field size and distance from field isocenter. RESULTS Formulas describing the exponential decrease of radiation dose to an unshielded and/or shielded fetus with distance from the field isocenter are presented. All fitted parameters of the above formulas can be easily derived using a set of graphs showing their correlation with field size. CONCLUSION This study describes a method of estimating fetal dose during brain radiotherapy, accounting for the effects of gestational age, field size and distance from field isocenter. Accurate knowledge of absorbed dose to the fetus before treatment course allows for the selection of the proper irradiation technique in order to achieve the maximum patient benefit with the least risk to the fetus.
Collapse
Affiliation(s)
- M Mazonakis
- Department of Medical Physics, University Hospital of Iraklion, Crete, Greece
| | | | | | | | | |
Collapse
|
46
|
Mazonakis M, Damilakis J, Theoharopoulos N, Varveris H, Gourtsoyiannis N. Brain radiotherapy during pregnancy: an analysis of conceptus dose using anthropomorphic phantoms. Br J Radiol 1999; 72:274-8. [PMID: 10396218 DOI: 10.1259/bjr.72.855.10396218] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The aims of this study were: (a) to determine conceptus dose resulting from brain radiotherapy; (b) to investigate the necessity of using shielding devices over patient's abdomen during treatment; and (c) to estimate the components of conceptus dose. Radiation doses received by conceptus were measured using anthropomorphic phantoms simulating pregnancy at 4, 12 and 24 weeks gestation and thermoluminescent dosemeters. All irradiations were performed with two lateral and opposed fields approximating the minimum, medium and maximum field size used during treatment of brain malignancies. For a treatment course delivering 65 Gy to tumour without using shielding equipment, conceptus dose never exceeded 100 mGy. Appropriate positioning of 5.1 cm of lead over the phantom's abdomen provided reduction of conceptus dose from 26% to 71%, depending upon gestational age, field size and distance from the field isocentre. The contribution of scatter arising from within the phantom to the conceptus dose was small compared with that from head leakage and collimator scatter. Our dosimetric results indicate that the construction of special shielding equipment is not a prerequisite for treating brain malignancies during pregnancy. However, based on the concept that exposures in women of childbearing age should be kept as low as reasonably achievable, we suggest that shielding devices should be used whenever possible.
Collapse
Affiliation(s)
- M Mazonakis
- Department of Medical Physics, University Hospital of Iraklion, Crete, Greece
| | | | | | | | | |
Collapse
|
47
|
Abstract
Malignant disease requiring radiation therapy during pregnancy presents an enormous challenge for the clinician. The optimal radiotherapeutic management of the patient and the optimal management of the pregnancy involve directly opposing demands. Ionizing radiation should be avoided during pregnancy whenever possible. Doses in excess of 0.1 Gy (10 rad) delivered during gestation have been associated with various detrimental effects, and therapeutic abortion has been recommended. If radiation is unavoidable, such as in the treatment of some gynecologic tumors, lymphomatous diseases, or other advanced solid tumors, it must be performed with extreme caution and maximal effort to reduce the dose to the fetus by special shielding techniques. Decisions regarding the use of radiation therapy during pregnancy, the delay of therapy, or pregnancy termination should be made by a multidisciplinary team and be guided by the prognosis of the disease, the stage of gestation, the risk to the fetus from the expected fetal radiation dose, and the patient's ethical and religious beliefs.
Collapse
Affiliation(s)
- N A Mayr
- Department of Radiology, University of Iowa College of Medicine, Iowa City, USA
| | | | | |
Collapse
|
48
|
Antypas C, Sandilos P, Kouvaris J, Balafouta E, Karinou E, Kollaros N, Vlahos L. Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 1998; 40:995-9. [PMID: 9531386 DOI: 10.1016/s0360-3016(97)00909-7] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE The aim of the work was to estimate the radiation dose delivered to the fetus in a pregnant patient irradiated for breast cancer. METHODS AND MATERIALS A 45-year woman was treated for left breast cancer using a 6 MV photon beam with two isocentric opposing tangential unwedged fields. Daily dose was 2.3 Gy at 95% isodose line given by two fields/day, 5 days/week. A total dose of 46 Gy was given in 20 fractions over a 4-week period. Pregnancy confirmed during the second therapeutic week. Treatment lasted between the second and sixth gestation week. Radiation dose to fetus was estimated from in vivo and phantom measurements using thermoluminescence dosimeters and an ionization chamber. In vivo measurements were performed by inserting either a catheter with TL dosimeters or ionization chamber into the patient's rectum. Phantom measurements were performed by simulating the treatment conditions on an anthropomorphic phantom. RESULTS TLD measurements (in vivo and phantom) revealed fetal dose to be 0.085% of the tumor dose, corresponding to a cumulative fetal dose of 3.9 cGy for the entire treatment of 46 Gy. Chamber measurements (in vivo and phantom) revealed a fetal dose less than the TLD result: 0.079 and 0.083% of the tumor dose corresponding to cumulative fetal dose of 3.6 cGy and 3.8 cGy for in vivo and phantom measurement, respectively. CONCLUSIONS It was concluded that the cumulative dose delivered to the unshielded fetus was 3.9 cGy for a 46 Gy total tumor dose. The estimated fetal dose is low compared to the total tumor dose given due to the early stage of pregnancy, the large distance between fundus-radiation field, and the fact that no wedges and/or lead blocks were used. No deterministic biological effects of radiation on the live-born embryo are expected. The lifetime risk for radiation-induced fatal cancer is higher than the normal incidence, but is considered as inconsequential.
Collapse
Affiliation(s)
- C Antypas
- Department of Radiology, Medical School, University of Athens, Areteion Hospital, Greece
| | | | | | | | | | | | | |
Collapse
|
49
|
Yu C, Luxton G, Apuzzo ML, MacPherson DM, Petrovich Z. Extracranial Radiation Doses in Patients Undergoing Gamma Knife Radiosurgery. Neurosurgery 1997. [DOI: 10.1227/00006123-199709000-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
50
|
Yu C, Luxton G, Apuzzo ML, MacPherson DM, Petrovich Z. Extracranial radiation doses in patients undergoing gamma knife radiosurgery. Neurosurgery 1997; 41:553-9; discussion 559-60. [PMID: 9310971 DOI: 10.1097/00006123-199709000-00009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE To determine extracranial doses in patients undergoing gamma knife radiosurgery and identify component sources of the extracranial doses using phantom measurements. METHODS The lateral canthi, thyroid, sternum, and midpelvis region were monitored in 104 unselected patients during their gamma knife treatments using thermoluminescent dosimetry. Measured doses were normalized to integral dose, equivalent time (which is defined in relation to the activity of the cobalt-60 sources), and collimator size to correlate radiation doses with these parameters. A phantom was constructed from a polystyrene sphere as a model of the head adjacent to thoracic and pelvic body sections from a commercial humanoid phantom. RESULTS On average, 18 minutes of equivalent time and five isocenters were required to achieve the prescribed dose coverage. The median prescribed dose was 18 Gy. For the lateral canthi, thyroid, sternum, and pelvis, the median doses were 24, 20, 21, and 4 cGy, respectively. Normalization to equivalent time and collimator size was superior to other techniques. Phantom measurements supported the results from patient measurements and further refined estimates of component doses to extracranial sites. CONCLUSION Doses to extracranial sites ranged from 1.5% of the prescribed dose for the lateral canthi to 0.2% for the pelvis. Doses to the sternum and pelvis were proportional to the duration of irradiation. Scatter radiation contributed more than 50% of the dose to the canthi and thyroid. Leakage radiation typically contributed 80 to 90% of the dose to the sternum and pelvis. Radiation during patient couch transit contributed little to the doses at the measured extracranial sites.
Collapse
Affiliation(s)
- C Yu
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles, USA
| | | | | | | | | |
Collapse
|